Shenzhen Chipscreen Biosciences Ltd. has synthesized MAPK-interacting kinase 1 (MNK1) and/or MAPK-interacting kinase 2 (MNK2) inhibitors reported to be useful for the treatment of cancer.
Shenzhen Chipscreen Biosciences Co. Ltd. has submitted an IND application for CS-231295 tablets for the treatment of tumors, and the application has been accepted by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA).
Biocytogen Pharmaceuticals Co. Ltd.’s wholly owned subsidiary, Eucure Biopharma Co. Ltd., licensed exclusive greater China rights to YH-008 to Chipscreen Biosciences Co. Ltd. in a ¥596 million (US$86 million) deal. Chipscreen subsidiary, Chipscreen Newway Biosciences Co. Ltd., will develop and commercialize the bispecific antibody in mainland China, Hong Kong, Macau and Taiwan.
Shenzhen Chipscreen Biosciences Ltd. has identified heterocyclic compounds acting as thyroid hormone receptor (THR) β agonists expected to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes, obesity, hyperlipidemia, hypothyroidism, atherosclerosis, thyroid cancer and hypercholesterolemia, among others.
Shenzhen Chipscreen Biosciences Co. Ltd.’s Bilessglu (chiglitazar), a peroxisome proliferator-activated receptor (PPAR) pan-agonist globally for the treatment of type 2 diabetes mellitus, has received marketing approval from the NMPA in China.
